SCHEMBL20006086

SCHEMBL20006086

Cc1ccc(OCCCOc2ccccc2C)c(C)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 11/20 0.56
MAPT P10636 8/20 0.56
HPGD P15428 6/20 0.55
RAB9A P51151 5/20 0.55
NPC1 O15118 4/20 0.55
SMN1; SMN2 Q16637 4/20 0.55
TDP1 Q9NUW8 2/20 0.55
ATM Q13315 2/20 0.55
MAPK1 P28482 2/20 0.55
TSHR P16473 1/20 0.55
CYP2C19 P33261 3/20 0.54
CYP1A2 P05177 2/20 0.54
CYP2C9 P11712 2/20 0.54
DRD2 P14416 2/20 0.54
DRD4 P21917 1/20 0.54
DRD3 P35462 1/20 0.54
CYP3A4 P08684 1/20 0.54
NFKB1 P19838 1/20 0.54
NFKB2 Q00653 1/20 0.54
KMT2A Q03164 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20006078 0.89 TSHR (0.60) L3MBTL1MAPTHPGDRAB9ANPC1
SCHEMBL9011867 0.86 SMN1; SMN2 (0.59) L3MBTL1MAPTHPGDRAB9ANPC1
SCHEMBL11679951 0.86 CYP2D6 (0.61) L3MBTL1MAPTHPGDRAB9ANPC1
SCHEMBL9011602 0.84 SMN1; SMN2 (0.57) L3MBTL1MAPTHPGDRAB9ANPC1
SCHEMBL9011659 0.84 SMN1; SMN2 (0.57) L3MBTL1MAPTHPGDRAB9ANPC1
SCHEMBL891407 0.84 SMN1; SMN2 (0.61) L3MBTL1MAPTHPGDRAB9ANPC1
SCHEMBL21118395 0.83 TSHR (0.57) L3MBTL1MAPTHPGDRAB9ANPC1
SCHEMBL9808080 0.82 ALDH1A1 (0.62) L3MBTL1MAPTHPGDRAB9ANPC1
SCHEMBL15605970 0.81 TSHR (0.59) L3MBTL1MAPTHPGDRAB9ANPC1
SCHEMBL12428 0.81 SMN1; SMN2 (0.54) L3MBTL1MAPTHPGDRAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10501413-B2 Inhibitors of the Notch transcriptional activation complex and methods for use of the same UNIVERSITY OF MIAMI (US) 2019-12-10 US disclosed
US-20180086700-A1 INHIBITORS OF THE NOTCH TRANSCRIPTIONAL ACTIVATION COMPLEX AND METHODS FOR USE OF THE SAME NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2018-03-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10501413-B2 Inhibitors of the Notch transcriptional activation complex and methods for use of the same NOTCH1, CBFB, HES1 L3MBTL1 805/4885MAPT 3938/4885HPGD 3369/4885
US-20180086700-A1 INHIBITORS OF THE NOTCH TRANSCRIPTIONAL ACTIVATION COMPLEX AND METHODS FOR USE OF THE SAME NOTCH1, CBFB, HES1 L3MBTL1 805/4885MAPT 3938/4885HPGD 3369/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.